Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
ACXP Stock Chart & Stats
$2.95
-$0.07(-8.37%)
At close: 4:00 PM EST
$2.95
-$0.07(-8.37%)
Day’s Range― - ―
52-Week Range$2.44 - $21.02
Previous CloseN/A
Volume243.54K
Average Volume (3M)1.14M
Market Cap
$6.86M
Enterprise Value$6.10M
Total Cash (Recent Filing)$5.91B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 12, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,348,113
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)22.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.34
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$30.50Price Target Upside933.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyIBZ demonstrated encouraging clinical efficacy in a Phase 2a/b study, showing success in treating C. diff infection with a high clinical cure rate.
Microbiome SelectivityIbezapolstat is further differentiated by its beneficial microbiome selectivity, likely contributing to enhanced efficacy in difficult to treat bacterial infections and de-risking late stage studies.
Regulatory ProgressThe end-of-Phase 2 meeting with the FDA has completed with alignment reached on the Phase 3 program, indicating regulatory progress.
Bears Say
Cash PositionThe company ended the quarter with approximately $5.9 million, which does not include $1.4 million from a recent warrant exercise.
Financial ConcernsAcurx reported a net loss of ($2.0M) for the third quarter, which might raise concerns about the company's financial standing.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $2.44 and its highest was $21.02 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $6.86M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Mar 12, 2026 which is in 60 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$1.23 earnings per share for the quarter, beating the consensus estimate of -$1.31 by $0.08.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -1.01.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 2,348,113 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$1.23 in its last earnings report, beating expectations of -$1.31. Following the earnings report the stock price went down -10.753%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as achieving NASDAQ compliance, patent expansion, and successful presentations, alongside ongoing financial challenges and significant reductions in R&D expenses. The company's improved financial position and strategic scientific advancements were notable, though the net loss and reduced R&D spending highlight areas of concern.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$30.50
▲(933.90% Upside)
Technical Analysis
Ibio
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Bolt Biotherapeutics
―